Skip to content
Open access

Bioequivalence of budesonide inhalation suspension with and without activated charcoal in healthy Chinese subjects: two randomized four-period crossover trials

Oct 2026 · Journal of Pharmacy & Pharmaceutical Sciences · Vol 29 · 0 citations · 16 references
Medicine

TL;DR

The charcoal-related findings are consistent with, but do not establish, a predominant pulmonary contribution to systemic exposure after nebulization and should be interpreted cautiously because the conditions were evaluated in separate cohorts.

Abstract

Background Demonstrating bioequivalence for locally acting inhaled products is challenging because systemic exposure may reflect both pulmonary absorption and gastrointestinal absorption of the swallowed fraction. Activated charcoal can suppress gastrointestinal uptake and may help interpret lung-derived exposure more directly. Methods Two open-label, randomized, single-dose, four-period crossover pharmacokinetic bioequivalence trials were conducted in healthy Chinese adults, one under non-block conditions and one under charcoal-block conditions. Thirty-six subjects were enrolled in each trial. In each period, subjects inhaled a single 1 mg dose of the test or reference budesonide inhalation suspension via a standardized jet nebulizer procedure, with a 5-day washout between periods. Plasma budesonide concentrations were measured for 15 h. The primary pharmacokinetic endpoints were Cmax, AUC0-t, and AUC0-inf, and bioequivalence was concluded if the 90% confidence intervals for the test/reference geometric mean ratios were within 80.00%–125.00%. Results Under both non-block and charcoal-block conditions, the 90% confidence intervals for Cmax, AUC0-t, and AUC0-inf met the predefined bioequivalence criteria. In exploratory between-cohort comparisons based on subject-level arithmetic summaries, activated-charcoal blockade was associated with numerically lower AUC values, whereas Cmax remained similar; however, nominal exploratory P values for Cmax, AUC0-t, and AUC0-inf were all >0.05 and were not used for confirmatory inference. These findings are consistent with, but do not establish, a predominant pulmonary contribution to systemic exposure after nebulization. Both formulations were well tolerated, and no serious adverse events were reported. Conclusion The test and reference budesonide inhalation suspension formulations were bioequivalent under both non-block and charcoal-block conditions. Exploratory between-cohort comparisons showed no statistically significant differences in Cmax, AUC0-t, or AUC0-inf based on nominal P values. The charcoal-related findings are consistent with, but do not establish, a predominant pulmonary contribution to systemic exposure after nebulization and should be interpreted cautiously because the conditions were evaluated in separate cohorts. Overall, the two studies provide supportive pharmacokinetic evidence for the evaluation of generic nebulized budesonide products. Trial Registration Clinical Trial Registration: Drug Clinical Trial Registration and Information Publicity Platform of the National Medical Products Administration of China, CTR20200344 and CTR20201473 (http://www.chinadrugtrials.org.cn/); Chinese Clinical Trial Registry, ChiCTR2000035173 (https://www.chictr.org.cn/).

Read PDF

Similar papers

Clinical trial Open access Sep 2026

Pharmacokinetic and Bioequivalence Evaluation of Febuxostat 40 mg Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions.

The objective of the current study was to evaluate the rate and extent of absorption, and confirm the bioequivalence of a test formulation and a reference formulation of febuxostat 40 mg tablets in healthy Chinese subjects under both fasting and fed conditions. An open-label, randomized, single-dose, single-center, two...

Ying Cao, Wen-Ping Wang, Xiao-Bin Li et al. · 0 citations
Open access Sep 2026

Pharmacokinetic and bioequivalence evaluation of teneligliptin hydrobromide tablets following single-dose administration in healthy Chinese volunteers under fasting and fed conditions

By inhibiting dipeptidyl peptidase-4 (DPP-4), teneligliptin provides a therapeutic option for type 2 diabetes mellitus (T2DM) that is widely used in Asia. A generic product could lessen treatment costs, provided that its systemic availability is equivalent to that of the branded formulation. Such comparative informatio...

Zhao-Feng Guan, Ming-Qi Chen, Bi-Ying Wei et al. · 0 citations
Open access Oct 2026

Bioequivalence study of two formulations of a sitagliptin/metformin hydrochloride extended-release tablet in healthy Chinese subjects under fasting and fed conditions: a randomized, open-label, single-dose, crossover trial

Introduction This study aimed to evaluate the bioequivalence and safety of a newly developed generic sitagliptin/metformin hydrochloride extended‐release (XR) tablet (50 mg/500 mg) compared with the reference formulation, Janumet XR, in healthy Chinese subjects under fasting and fed conditions. Methods This randomized,...

Lin Fang, Xin Li, Rong-Xin Ban et al. · 0 citations
Open access Nov 2026

Bioequivalence of a Hydroxyurea Oral Suspension (100 mg/mL) and Xromi® 100 mg/mL Oral Solution (100 mg Hydroxycarbamide) under Fasting Conditions: A Randomised, Open-label, Single-dose, Two-period Crossover Study

Introduction: Hydroxyurea oral suspension is approved as an adjunctive treatment for Sickle Cell Disease (SCD) and Myeloproliferative Disorders (MPD). Oral liquid formulations ensure accurate dose administration, improve ease of use in patients with difficulty swallowing solid dosage forms, and may be administered with...

S. Jaiswal, Arun Chaudhary, Mamta Sharma et al. · 0 citations
Open access Oct 2026

Pharmacokinetic and Bioequivalence of Mirtazapine Orally Disintegrating Tablets: A Randomized, Crossover Study.

The study aimed to assess the bioequivalence of a new generic orally disintegrating tablet (ODT) formulation containing mirtazapine 30 mg with the reference formulation, and to support biowaiver for an additional 15 mg strength. Fifty-five healthy Malaysian males completed an open-label, balanced, randomized, 2-treatme...

Kai Bin Liew, K. M. Yee, Jeyashanthini Nalaiya et al. · 0 citations
Open access Sep 2026

A Novel Lorazepam Orodispersible Film: Bioequivalence, Pharmacokinetic, and Tolerability Evaluation Compared with Film-Coated and Orodispersible Tablets in Two Randomized Crossover Studies in Healthy Subjects

Introduction: Lorazepam is a widely prescribed benzodiazepine available in multiple pharmaceutical formulations. A novel lorazepam orodispersible film (ODF) has been developed as an alternative dosage form designed to address administration challenges and enhance treatment adherence. Its pharmacokinetic profile, includ...

Valeria Frangione, Cristina Sensi, M. Radicioni et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.